RAPT stock trades at $58.02 intraday on 04 Mar 2026 ahead of an earnings release scheduled for 05 Mar 2026. The market is pricing in clinical and messaging milestones more than revenue, given RAPT Therapeutics, Inc.’s clinical-stage profile on the NASDAQ in the United States. Key intraday stats: volume 10,846,697, market cap $959.51M, and EPS -11.66. We note the company’s lead assets, RPT193 and FLX475, remain the likely drivers in tomorrow’s call. For live quote and company context, see our Meyka stock page and the latest market coverage MarketBeat and Investing.com. Meyka AI provides this AI-powered market analysis to frame risks and possible moves

RAPT stock: Earnings timing and expected drivers

Earnings are scheduled for 05 Mar 2026 and the report will focus on clinical updates, not product sales. RAPT Therapeutics is clinical-stage and reports no recurring revenue, so management commentary on trial timelines matters most. Investors should watch statements on RPT193 and FLX475 enrollment, safety readouts, and any guidance on partnership or M&A activity.

RAPT stock: Intraday price action and liquidity signals

RAPT stock is trading between $57.98 and $58.02 intraday with volume at 10,846,697, well above the 50-day average. The relative volume is about 4.08x, signaling heavy interest ahead of earnings. Technicals show RSI 79.78, an overbought reading, and Bollinger upper band near $58.04, pointing to short-term momentum and risk of a pullback after the report.

RAPT stock: Fundamentals and valuation snapshot

RAPT Therapeutics carries a market cap of $959.51M and negative earnings per share of -11.66. The reported PE sits at -4.98, and price-to-book is 10.29. Cash per share is 5.84 and current ratio is 12.04, indicating a strong liquidity cushion for further trials. As a clinical-stage biotech, standard valuation multiples can be misleading without clinical readouts.

RAPT stock: Analyst views, institutional flows and news

Brokerage coverage is mixed: 7 Buy and 6 Hold ratings produce a consensus near Hold. MarketBeat lists a consensus price target of $48.44, while JPMorgan has set $57.00 and Barclays $58.00. Institutional ownership is very high at 99.09%, and short interest fell by 30.5% in February. Recent headlines include an Investing.com report on potential acquisition-related actions, which investors should confirm during the earnings call.

RAPT stock: Meyka AI grade and technical outlook

Meyka AI rates RAPT with a score of 68.20 out of 100 (Grade B, HOLD). This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, analyst consensus, and forecasts. Technically, ADX 65.15 shows a strong trend, while MACD histogram is negative, suggesting momentum may slow. Near-term price targets range from the consensus $48.44 to Meyka AI’s quarterly forecast $64.74.

Final Thoughts

RAPT stock sits at $58.02 with earnings due on 05 Mar 2026, making tomorrow’s call the primary short-term catalyst. Clinical-readout updates, trial timelines for RPT193 and FLX475, and any commentary on partnerships will move the stock more than conventional sales metrics. Meyka AI’s forecast model projects a near-term quarterly target of $64.74, implying an upside of 11.58% from today’s price. By contrast, consensus targets cluster near $48.44, implying downside risk if clinical news disappoints. Institutional ownership and a sharp drop in short interest suggest reduced speculative pressure, but technical indicators warn of overbought conditions. Forecasts are model-based projections and not guarantees. Use the earnings call to update probabilities on binary clinical outcomes and adjust position sizing to reflect RAPT Therapeutics, Inc.’s NASDAQ-listed, United States biotech risk profile.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.